Milestone Pharmaceuticals (NASDAQ:MIST) Downgraded by Zacks Investment Research

Zacks Investment Research lowered shares of Milestone Pharmaceuticals (NASDAQ:MIST) from a hold rating to a sell rating in a research report released on Saturday morning, Zacks.com reports.

According to Zacks, “Milestone Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing and commercializing the investigational new drug etripamil for the treatment of cardiovascular indications. The company’s lead product candidate consists of MSP-2017, a nasal spray. Milestone Pharmaceuticals Inc. is based in Montréal, Canada. “

Several other equities research analysts have also recently issued reports on the stock. ValuEngine upgraded shares of Milestone Pharmaceuticals from a hold rating to a buy rating in a research report on Tuesday, October 1st. Cowen reiterated a buy rating and set a $32.00 price objective on shares of Milestone Pharmaceuticals in a research report on Thursday, November 14th. One research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock currently has a consensus rating of Buy and an average target price of $30.10.

Shares of Milestone Pharmaceuticals stock traded up $0.42 on Friday, hitting $18.00. 388 shares of the company traded hands, compared to its average volume of 3,874. Milestone Pharmaceuticals has a 52 week low of $15.09 and a 52 week high of $27.95. The company’s 50-day moving average price is $18.95.

Milestone Pharmaceuticals (NASDAQ:MIST) last released its quarterly earnings data on Wednesday, November 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.04). Sell-side analysts expect that Milestone Pharmaceuticals will post -3.29 earnings per share for the current fiscal year.

In other Milestone Pharmaceuticals news, major shareholder Rtw Investments, Lp purchased 5,487 shares of Milestone Pharmaceuticals stock in a transaction that occurred on Tuesday, October 15th. The shares were bought at an average price of $18.95 per share, for a total transaction of $103,978.65. Also, major shareholder Stonepine Capital, L.P. purchased 100,000 shares of Milestone Pharmaceuticals stock in a transaction that occurred on Friday, October 11th. The stock was acquired at an average price of $0.63 per share, for a total transaction of $63,000.00. Insiders purchased 113,637 shares of company stock worth $311,967 in the last 90 days.

A number of institutional investors and hedge funds have recently made changes to their positions in MIST. Tower Research Capital LLC TRC bought a new stake in Milestone Pharmaceuticals in the second quarter worth $51,000. Landscape Capital Management L.L.C. bought a new stake in Milestone Pharmaceuticals in the second quarter worth $459,000. Pentwater Capital Management LP bought a new stake in Milestone Pharmaceuticals in the second quarter worth $679,000. VHCP Management II LLC bought a new stake in Milestone Pharmaceuticals in the second quarter worth $4,033,000. Finally, Zimmer Partners LP bought a new stake in Milestone Pharmaceuticals in the second quarter worth $4,344,000. Institutional investors own 53.33% of the company’s stock.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes drugs for the treatment of cardiovascular indications. It offers Etripamil that completed Phase 2 clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada, as well as for treating Atrial Fibrillation and Angina.

See Also: Monthly Dividend Stocks Can Provide Solid Income

Get a free copy of the Zacks research report on Milestone Pharmaceuticals (MIST)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Milestone Pharmaceuticals (NASDAQ:MIST)

Receive News & Ratings for Milestone Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Milestone Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.